HepQuant Announces Approval of First Investigational Device Exemption Application

HepQuant SHUNT™ Liver Diagnostic Kit for use in a clinical study in subjects with Alcoholic Hepatitis

DENVER, CO (March 9, 2017) -- HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that its first application for an Investigational Device Exemption ("IDE") for its HepQuant SHUNT™ Liver Diagnostic Kit has been approved by the Food and Drug Administration ("FDA") for use in a clinical study in subjects with Alcoholic Hepatitis. Alcoholic hepatitis is a syndrome of progressive inflammatory liver injury associated with long-term heavy intake of alcohol over an extended period of time.

Founder and Chief Executive Officer of HepQuant, LLC, Dr. Gregory T. Everson is encouraged by this milestone, stating, "In cases of Alcoholic Hepatitis, assessment of disease severity may be important because disease severity impacts prognosis. More generally, the IDE approval is an important step for our company because it permits us to collect safety and effectiveness data that will be required to support a premarket approval application to the FDA."

About HepQuant

HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.

MEDIA CONTACT
Tom Kennedy, Corporate Communications
Ph: (303) 548-3056 | E: tom.kennedy@hepquant.com